Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 928M 815M 751M 702M 1.32B 87.54B 1.34B 9.01B 3.49B 43.15B 3.48B 3.41B 150B P/E 2026 *
15.7x
P/E 2027 * 12x
Enterprise Value 1.24B 1.09B 1B 937M 1.76B 117B 1.79B 12.03B 4.66B 57.61B 4.65B 4.55B 200B EV / Sales 2026 *
1.66x
EV / Sales 2027 * 1.4x
Free-Float
50.3%
Yield 2026 *
-
Yield 2027 * -
1 day+0.10%
1 week+11.86%
Current month+11.62%
1 month+14.29%
3 months+7.51%
6 months-21.52%
Current year-21.43%
1 week 18.22
Extreme 18.22
22
1 month 17.73
Extreme 17.73
22
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
67.66
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 29/02/1996
Chief Operating Officer 76 29/02/1996
Director of Finance/CFO 58 01/04/2014
Director TitleAgeSince
Chairman 76 29/02/1996
Director/Board Member 79 29/02/1996
Director/Board Member 58 04/08/2022
Date Insider Type Main position Quantity % Market Cap.
06-02Tax

Director

-769 0.0017%
06-01Free

Director

25,508 0.0579%
06-01Free

Director

25,508 0.0579%
Change 5-day change 1-year change 3-year change Capi.($)
+0.10%+11.86%-10.28%-63.19% 928M
+0.93%+2.65%+42.33%+145.77% 1,006B
+1.61%+7.22%+60.81%+47.98% 589B
+3.51%+12.31%+31.15%+78.88% 430B
+0.99%+5.11%+29.26%+21.27% 331B
+1.09%+6.90%+37.22%+23.11% 288B
+1.34%+6.74%+32.63%+38.93% 285B
+1.32%+12.69%-27.48%-42.00% 213B
+0.40%+4.51%+25.85%+55.35% 190B
-1.05%+0.06%+16.91%+59.86% 154B
Average +1.02%+6.19%+23.84%+36.60% 348.67B
Weighted average by Cap. +1.32%+5.38%+35.32%+70.06%

Financials

2026 *2027 *
Net sales 747M 656M 604M 565M 1.06B 70.47B 1.08B 7.25B 2.81B 34.74B 2.8B 2.74B 121B 788M 693M 638M 597M 1.12B 74.4B 1.14B 7.66B 2.97B 36.67B 2.96B 2.9B 127B
Net income 64M 56.22M 51.8M 48.43M 90.83M 6.04B 92.5M 621M 241M 2.98B 240M 235M 10.35B 84M 73.79M 67.98M 63.56M 119M 7.93B 121M 816M 316M 3.91B 315M 309M 13.58B
Net Debt 311M 273M 251M 235M 441M 29.32B 449M 3.02B 1.17B 14.45B 1.17B 1.14B 50.23B 173M 152M 140M 131M 246M 16.36B 251M 1.68B 652M 8.07B 651M 637M 28.03B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
25/06/26 $21.04 +0.10% 481,265
24/06/26 $21.02 +7.63% 701,214
23/06/26 $19.53 +6.55% 660,872
22/06/26 $18.33 -2.55% 767,439
18/06/26 $18.81 -3.09% 1,327,603
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
21.04USD
Average target price
22.83USD
Spread / Average Target
+8.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock